Journal Reading

and efficacy of cardiac ESWT in the patients with concomitant EnD-CAD and
ESRD.This journal was prospective study between August 2016 and January 2019.
The result of this journal All participants tolerated cardiac ESWT without any
relevant side effects such as skin allergic reaction, local redness/tenderness or cardiac
arrhythmia. There were similar baseline comorbidities and clinical features between
two groups, but the EnD-CAD/ESRD group had significantly higher serum potassium
level as well as lower renal function and lipid profile (all p-values <0.03). After
cardiac ESWT, the patients in both groups had significant improvement in angina and
dyspnea at 1 year (all p-values <0.03). However, the EnD-CAD/ESRD group did not
have increase in either circulating EPC levels or LVEF at 6 months (p 1.000). In
contrast, the EnD-CAD group had gradually improving levels of circulating EPC
surface markers and increased LV systolic function (p 0.092). Notably, patients in the
EnD-CAD/ESRD group suffered from high incidental clinical adverse events before
and after enrollment into the ESWT study (p 0.132).
The conclusion of this journal is although cardiac ESWT provided
mprovement of clinical symptoms in the EnD-CAD patients, its long-term effects on
the angiogenesis and LVEF were reduced for those high-risk patients with
concomitant EnD-CAD and ESRD.

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death

worldwide with a growing incidence, according for more than 15 million global
deaths annually. Of them, although diffuse coronary artery disease (CAD) occurred in
less than 5% of ASCVD, it has significantly higher risk for heart failure or sudden
cardiac death compared with single or multiple vessel CAD. Patients with ASCVD
usually have multiple vascular involvement and comorbidities due to sharing
common atherosclerotic risk factors and pathology of chronic systemic inflammation.
Kidney involvement was usually observed in patients with diffuse CAD , especially
for those with poorly controlled diabetes. Unfortunately, even with efforts in treating
and preventing progression of chronic kidney disease (CKD), a part of patients with
CAD and CKD eventually developed end-stage renal disease (ESRD).
.This was a single-center prospective study to test the
safety